Beranda › Kanker Orofaring
Uji klinis Kanker Orofaring yang merekrut di AS
52 studi untuk Kanker Orofaring merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Edison, NJ8 studi
- Atlanta, GA8 studi
- Chicago, IL7 studi
- New York City, NY6 studi
- Queens, NY5 studi
- Los Angeles, CA5 studi
- Philadelphia, PA5 studi
- Pittsburgh, PA5 studi
- Milwaukee, WI5 studi
- St. Louis, MO5 studi
- Omaha, NE5 studi
- Kansas City, MO5 studi
- Houston, TX5 studi
- Tampa, FL5 studi
- Rochester, MN4 studi
- Staten Island, NY4 studi
- Greenburgh, NY4 studi
- East Norwalk, CT4 studi
- Ann Arbor, MI4 studi
- Overland Park, KS4 studi
- Kansas City, KS4 studi
- Detroit, MI4 studi
- Naperville, IL4 studi
- Durham, NC4 studi
- Washington, DC4 studi
- Richmond, VA4 studi
- Baltimore, MD4 studi
- New Rochelle, NY3 studi
- Portland, OR3 studi
- West Bend, WI3 studi
- Champaign, IL3 studi
- Oklahoma City, OK3 studi
- Charleston, IL3 studi
- Danville, IL3 studi
- Des Moines, IA3 studi
- Stevens Point, WI3 studi
- North Peoria, IL3 studi
- Bloomington, IL3 studi
- Aurora, IL3 studi
- Jacksonville, FL3 studi
Berdasarkan negara bagian
- Arizona4 studi
- California9 studi
- Colorado4 studi
- Distrik Columbia3 studi
- Florida12 studi
- Georgia8 studi
- Illinois8 studi
- Iowa5 studi
- Kansas5 studi
- Kentucky3 studi
- Maryland7 studi
- Massachusetts4 studi
- Michigan6 studi
- Minnesota6 studi
- Missouri9 studi
- Nebraska5 studi
- New Hampshire3 studi
- New Jersey8 studi
- New York11 studi
- North Carolina6 studi
- North Dakota3 studi
- Ohio8 studi
- Oklahoma4 studi
- Oregon3 studi
- Pennsylvania10 studi
- South Carolina3 studi
- Tennessee3 studi
- Texas6 studi
- Vermont3 studi
- Virginia4 studi
- Wisconsin6 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05541016Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06997068Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07195734Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly
Menerima peserta
Usia 65 hingga 99 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06309225BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06305676Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05172245Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05880797Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07441681Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Menerima pesertaFase 2
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT04900623Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06254911Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06445114Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766The Minimalist Trial-2
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06702033Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT05388773Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06662058pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05799144Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT01365169Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07178301SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT05451004Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT04151082E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT05686226Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.